Please assess the completion status of the following clinical trial:

Trial Title: Dietary Flaxseed in NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, ages 18 and older~* Current diagnosis of non-small cell lung cancer (NSCLC) including patients who have metastatic disease requiring definitive thoracic and mediastinal radiotherapy with concurrent chemotherapy.~* Able to provide written informed consent and comply with all study procedures~* Total planned radiation dose to gross disease 60-70 Gy.~Exclusion Criteria:~* Current diagnosis of disease of the gastrointestinal system, liver, or kidneys which could result in altered metabolism or excretion of the study medication (history of major gastrointestinal tract surgery, gastrectomy, gastrostomy, bowel resection, etc.) or history of chronic gastrointestinal disorders (ulcerative colitis, regional enteritis, or gastrointestinal bleeding)~* Known hypersensitivity to flaxseed or any of its metabolites, or wheat products~* Taking or has taken an investigational drug within 14 days.~* Taking or has taken Amifostine or Mucomyst (N-acetylcysteine) within 14 days~* Current or prior use of flaxseed, flax-containing products, soybeans, or soy-containing products~* Current or prior use (limited to prior 14 days) of dietary supplements such as herbals or botanicals~* Prior thoracic and/or mediastinal radiation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dietary Supplement: Flaxseed (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).